|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Therapeutic potential of colchicine in cardiovascular medicine:a pharmacological review显示文摘Colchicine is an ancient herbal drug derived from Colchicum autumnale.It was first used to treat familial Mediterranean fever and gout.Based on its unique efficacy as an anti-inflammatory agent,colchicine has been used in the therapy of cardiovascular diseases including coronary artery disease,atherosclerosis,recurrent pericarditis,vascular restenosis,heart failure,and myocardial infarction.More recently,colchicine has also shown therapeutic efficacy in alleviating cardiovascular complications of COVID-19.COLCOT and LoDoCo2 are two milestone clinical trials that confirm the curative effect of long-term administration of colchicine in reducing the incidence of cardiovascular events in patients with coronary artery disease.There is growing interest in studying the anti-inflammatory mechanisms of colchicine.The anti-inflammatory action of colchicine is mediated mainly through inhibiting the assembly of microtubules.At the cellular level,colchicine inhibits the following:(1)endothelial cell dysfunction and inflammation;(2)smooth muscle cell proliferation and migration;(3)macrophage chemotaxis,migration,and adhesion;(4)platelet activation.At the molecular level,colchicine reduces proinflammatory cytokine release and inhibits NF-κB signaling and NLRP3 inflammasome activation.In this review,we summarize the current clinical trials with proven curative effect of colchicine in treating cardiovascular diseases.We also systematically discuss the mechanisms of colchicine action in cardiovascular therapeutics.Altogether,colchicine,a bioactive constituent from an ancient medicinal herb,exerts unique anti-inflammatory effects and prominent cardiovascular actions,and will charter a new page in cardiovascular medicine. | Fan-shun Zhang Qing-ze He Chengxue Helena Qin Peter JLittle Jian-ping Weng Suo-wen Xu | 2022 | Acta Pharmacologica Sinica2022，43，9： | 5 |
| 2 | Anti-atherosclerotic effects and molecular targets of ginkgolide B from Ginkgo biloba显示文摘Bioactive compounds derived from herbal medicinal plants modulate various therapeutic targets and signaling pathways associated with cardiovascular diseases(CVDs),the world’s primary cause of death.Ginkgo biloba,a well-known traditional Chinese medicine with notable cardiovascular actions,has been used as a cardio-and cerebrovascular therapeutic drug and nutraceutical in Asian countries for centuries.Preclinical studies have shown that ginkgolide B,a bioactive component in Ginkgo biloba,can ameliorate atherosclerosis in cultured vascular cells and disease models.Of clinical relevance,several clinical trials are ongoing or being completed to examine the efficacy and safety of ginkgolide B-related drug preparations in the prevention of cerebrovascular diseases,such as ischemia stroke.Here,we present a comprehensive review of the pharmacological activities,pharmacokinetic characteristics,and mechanisms of action of ginkgolide B in atherosclerosis prevention and therapy.We highlight new molecular targets of ginkgolide B,including nicotinamide adenine dinucleotide phosphate oxidases(NADPH oxidase),lectin-like oxidized LDL receptor-1(LOX-1),sirtuin 1(SIRT1),platelet-activating factor(PAF),proprotein convertase subtilisin/kexin type 9(PCSK9)and others.Finally,we provide an overview and discussion of the therapeutic potential of ginkgolide B and highlight the future perspective of developing ginkgolide B as an effective therapeutic agent for treating atherosclerosis. | Weile Ye Jiaojiao Wang Peter JLittle Jiami Zou Zhihua Zheng Jing Lu Yanjun Yin Hao Liu Dongmei Zhang Peiqing Liu Suowen Xu Wencai Ye Zhiping Liu | 2024 | Acta Pharmaceutica Sinica B2024，14，1： | 0 |
| 3 | Targeting protein modifications in metabolic diseases:molecular mechanisms and targeted therapies显示文摘The ever-increasing prevalence of noncommunicable diseases(NCDs)represents a major public health burden worldwide.The most common form of NCD is metabolic diseases,which affect people of all ages and usually manifest their pathobiology through life-threatening cardiovascular complications.A comprehensive understanding of the pathobiology of metabolic diseases will generate novel targets for improved therapies across the common metabolic spectrum.Protein posttranslational modification(PTM)is an important term that refers to biochemical modification of specific amino acid residues in target proteins,which immensely increases the functional diversity of the proteome.The range of PTMs includes phosphorylation,acetylation,methylation,ubiquitination,SUMOylation,neddylation,glycosylation,palmitoylation,myristoylation,prenylation,cholesterylation,glutathionylation,S-nitrosylation,sulfhydration,citrullination,ADPribosylation,and several novel PTMs.Here,we offer a comprehensive review of PTMs and their roles in common metabolic diseases and pathological consequences,including diabetes,obesity,fatty liver diseases,hyperlipidemia,and atherosclerosis.Building upon this framework,we afford a through description of proteins and pathways involved in metabolic diseases by focusing on PTM-based protein modifications,showcase the pharmaceutical intervention of PTMs in preclinical studies and clinical trials,and offer future perspectives.Fundamental research defining the mechanisms whereby PTMs of proteins regulate metabolic diseases will open new avenues for therapeutic intervention. | Xiumei Wu Mengyun Xu Mengya Geng Shuo Chen Peter JLittle Suowen Xu Jianping Weng | 2023 | Signal Transduction and Targeted Therapy2023，8，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员